Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
JAMA Oncology|October 3, 2024
Fracture Risk Prediction Using the Fracture Risk Assessment Tool in Individuals With CancerCarrie Ye, William D Leslie, Saeed Al-Azazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2008
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
American Journal of Physiology. Heart and Circulatory Physiology|December 1, 2018
Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunctionViktoriya Mozolevska, Anna Schwartz, David Cheung, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 19, 2017
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experienceAly-Khan A Lalani, Haocheng Li, Daniel Y C Heng, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, et al.
Pageof 4